Haemonetics Corporation (HAE)
NYSE
119.47
+17.76 (+17.46%)
Closed
Oct 8, 2026
Day's Range
111.66121.00
52 wk Range
48.17121.00
Financial Statements - HAE - Haemonetics Corporation
Revenue
1.33B▼ 2.0%
Net Income
97.30M▼ 42.0%Net Margin 7.3%
EBITDA
353.11M▲ 11.5%
Free Cash Flow
260.44M▲ 82.8%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 1.33B | 1.36B | 1.30B | 1.16B | 993.19M | 870.46M |
| Cost of Goods | 546.44M | 611.86M | 617.50M | 553.56M | 487.69M | 472.62M |
| Gross Profit | 787.58M | 748.95M | 691.54M | 615.09M | 505.50M | 397.83M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 241.40M | 201.18M | 173.30M | 155.65M | 71.14M | 56.93M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -84.66M | 20.63M | -8.41M | 382K | 9.60M | 32.81M |
| Pre Tax Income | 128.03M | 212.07M | 151.86M | 141.40M | 63.62M | 72.91M |
| Income Tax | 30.72M | 44.39M | 34.30M | 26M | 20.25M | -6.55M |
| Net Income | 97.30M | 167.67M | 117.55M | 115.40M | 43.37M | 79.46M |
| EPS Basic | 2.062528 | 3.331591 | 2.32 | 2.27 | 0.849707 | 1.567807 |
| EPS Diluted | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 | 1.55 |
| Basic Shares Outstanding | 47.17M | 50.33M | 50.70M | 50.78M | 51.04M | 50.68M |
| Diluted Shares Outstanding | 47.17M | 50.33M | 50.70M | 50.78M | 51.04M | 50.68M |
| Ebit | 156.73M | 221.81M | 164.88M | 156.03M | 80.75M | 89.74M |
| Ebitda | 353.11M | 316.77M | 270.51M | 248.95M | 168.89M | 141.22M |
| Net Income Continuous Operations | 97.30M | 167.67M | 117.55M | 115.40M | 43.37M | 79.46M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
